436 related articles for article (PubMed ID: 25535823)
21. Dietary DHA amplifies LXA
Gao Y; Su J; Zhang Y; Chan A; Sin JH; Wu D; Min K; Gronert K
Mucosal Immunol; 2018 Nov; 11(6):1674-1683. PubMed ID: 30104626
[TBL] [Abstract][Full Text] [Related]
22. Addressing excessive evaporation: an unmet need in dry eye disease.
Karpecki PM; Nichols KK; Sheppard JD
Am J Manag Care; 2023 Oct; 29(13 Suppl):S239-S247. PubMed ID: 37844320
[TBL] [Abstract][Full Text] [Related]
23. Characterization of effector T cells in dry eye disease.
El Annan J; Chauhan SK; Ecoiffier T; Zhang Q; Saban DR; Dana R
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3802-7. PubMed ID: 19339740
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiology of dry eye disease and novel therapeutic targets.
Messmer EM
Exp Eye Res; 2022 Apr; 217():108944. PubMed ID: 35077753
[TBL] [Abstract][Full Text] [Related]
25. TRI Microspheres prevent key signs of dry eye disease in a murine, inflammatory model.
Ratay ML; Balmert SC; Acharya AP; Greene AC; Meyyappan T; Little SR
Sci Rep; 2017 Dec; 7(1):17527. PubMed ID: 29235530
[TBL] [Abstract][Full Text] [Related]
26. Ocular surface immune cell diversity in dry eye disease.
Nair AP; D'Souza S; Khamar P; Nuijts RMMA; Sethu S; Shetty R
Indian J Ophthalmol; 2023 Apr; 71(4):1237-1247. PubMed ID: 37026254
[TBL] [Abstract][Full Text] [Related]
27. Impact of aging on the pathophysiology of dry eye disease: A systematic review and meta-analysis.
Kitazawa K; Inomata T; Shih K; Hughes JB; Bozza N; Tomioka Y; Numa K; Yokoi N; Campisi J; Dana R; Sotozono C
Ocul Surf; 2022 Jul; 25():108-118. PubMed ID: 35753664
[TBL] [Abstract][Full Text] [Related]
28. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression.
Chauhan SK; El Annan J; Ecoiffier T; Goyal S; Zhang Q; Saban DR; Dana R
J Immunol; 2009 Feb; 182(3):1247-52. PubMed ID: 19155469
[TBL] [Abstract][Full Text] [Related]
29. IFN-γ-Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity.
Chen Y; Chauhan SK; Shao C; Omoto M; Inomata T; Dana R
J Immunol; 2017 Aug; 199(3):1163-1169. PubMed ID: 28637904
[TBL] [Abstract][Full Text] [Related]
30. Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease.
Reyes JL; Vannan DT; Eksteen B; Avelar IJ; Rodríguez T; González MI; Mendoza AV
Mediators Inflamm; 2018; 2018():2532314. PubMed ID: 30158831
[TBL] [Abstract][Full Text] [Related]
31. Systemic Conditions Associated with Severity of Dry Eye Signs and Symptoms in the Dry Eye Assessment and Management Study.
Yu K; Bunya V; Maguire M; Asbell P; Ying GS;
Ophthalmology; 2021 Oct; 128(10):1384-1392. PubMed ID: 33785415
[TBL] [Abstract][Full Text] [Related]
32. The Molecular Mechanisms Responsible for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Dry Eye Disease Patients.
Harrell CR; Feulner L; Djonov V; Pavlovic D; Volarevic V
Cells; 2023 Dec; 12(23):. PubMed ID: 38067183
[TBL] [Abstract][Full Text] [Related]
33. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
[TBL] [Abstract][Full Text] [Related]
34. Mucosal immunology of the ocular surface.
de Paiva CS; St Leger AJ; Caspi RR
Mucosal Immunol; 2022 Jun; 15(6):1143-1157. PubMed ID: 36002743
[TBL] [Abstract][Full Text] [Related]
35. Rabbit models of dry eye disease: Current understanding and unmet needs for translational research.
Singh S; Sharma S; Basu S
Exp Eye Res; 2021 May; 206():108538. PubMed ID: 33771517
[TBL] [Abstract][Full Text] [Related]
36. Dry eye disease as an inflammatory disorder.
Calonge M; Enríquez-de-Salamanca A; Diebold Y; González-García MJ; Reinoso R; Herreras JM; Corell A
Ocul Immunol Inflamm; 2010 Aug; 18(4):244-53. PubMed ID: 20482396
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of ocular surface status and function in primary Sjögren's syndrome with hypothyroidism].
Yu HZ; Zeng WZ; Wu WY; Yao ZQ; Feng Y
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):705-711. PubMed ID: 35950396
[TBL] [Abstract][Full Text] [Related]
38. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease.
Ratay ML; Balmert SC; Bassin EJ; Little SR
Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828
[TBL] [Abstract][Full Text] [Related]
39. Immune profile of squamous metaplasia development in autoimmune regulator-deficient dry eye.
Chen YT; Li S; Nikulina K; Porco T; Gallup M; McNamara N
Mol Vis; 2009; 15():563-76. PubMed ID: 19365590
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers of ocular allergy and dry eye disease.
Zemba M; Ionescu MA; Pîrvulescu RA; Dumitrescu OM; Daniel-Constantin B; Radu M; Stamate AC; Istrate S
Rom J Ophthalmol; 2023; 67(3):250-259. PubMed ID: 37876509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
